PURPOSE: The purpose of this study was to evaluate the systemic and ocular pharmacokinetics (PK) of fluocinolone acetonide (FAc) following administration of Iluvien(®) intravitreal implants. METHODS: The FAc intravitreal implant was administered to rabbits in 3 doses (0.2, 0.5, and 1.0 μg/day). The concentration of FAc was measured by a validated liquid chromatography-mass spectrometry/mass spectrometry (LC-MS/MS) method in plasma and ocular tissues at various time points through month 24. RESULTS: Following administration of the 0.2 μg/day implant, FAc levels peaked in most tissues at day 2 or 8, reached approximate steady state levels by month 3 and very gradually decreased over the duration of the study. The FAc level in the aqueous humor was not measurable at most time points in the rabbit. FAc was still present in most ocular tissues at 2 years. The 0.5 and 1.0 μg/day dose groups followed the same pattern through month 9. The elimination half lives in the tissues for which it was measurable were greater than 83 days. Exposure to FAc was highest in the choroid/retinal pigment epithelium for all doses, followed by lens and retina. CONCLUSIONS: The results of this study demonstrate sustained delivery of FAc from the Iluvien intravitreal implant in the ocular tissue of rabbits. Retina and lens FAc levels with the Iluvien implant were approximately 1/10 those reported with the Retisert(®) implant. FAc levels in the aqueous were not measureable with Iluvien where they were measured for 12 months with Retisert.
PURPOSE: The purpose of this study was to evaluate the systemic and ocular pharmacokinetics (PK) of fluocinolone acetonide (FAc) following administration of Iluvien(®) intravitreal implants. METHODS: The FAc intravitreal implant was administered to rabbits in 3 doses (0.2, 0.5, and 1.0 μg/day). The concentration of FAc was measured by a validated liquid chromatography-mass spectrometry/mass spectrometry (LC-MS/MS) method in plasma and ocular tissues at various time points through month 24. RESULTS: Following administration of the 0.2 μg/day implant, FAc levels peaked in most tissues at day 2 or 8, reached approximate steady state levels by month 3 and very gradually decreased over the duration of the study. The FAc level in the aqueous humor was not measurable at most time points in the rabbit. FAc was still present in most ocular tissues at 2 years. The 0.5 and 1.0 μg/day dose groups followed the same pattern through month 9. The elimination half lives in the tissues for which it was measurable were greater than 83 days. Exposure to FAc was highest in the choroid/retinal pigment epithelium for all doses, followed by lens and retina. CONCLUSIONS: The results of this study demonstrate sustained delivery of FAc from the Iluvien intravitreal implant in the ocular tissue of rabbits. Retina and lens FAc levels with the Iluvien implant were approximately 1/10 those reported with the Retisert(®) implant. FAc levels in the aqueous were not measureable with Iluvien where they were measured for 12 months with Retisert.
Authors: Peter A Campochiaro; David M Brown; Andrew Pearson; Sanford Chen; David Boyer; Jose Ruiz-Moreno; Bruce Garretson; Amod Gupta; Seenu M Hariprasad; Clare Bailey; Elias Reichel; Gisele Soubrane; Barry Kapik; Kathleen Billman; Frances E Kane; Kenneth Green Journal: Ophthalmology Date: 2012-06-21 Impact factor: 12.079
Authors: Jean-Yves Driot; Gary D Novack; Kay D Rittenhouse; Chris Milazzo; P Andrew Pearson Journal: J Ocul Pharmacol Ther Date: 2004-06 Impact factor: 2.671
Authors: Peter A Campochiaro; Quan Dong Nguyen; Gulnar Hafiz; Steven Bloom; David M Brown; Miguel Busquets; Thomas Ciulla; Leonard Feiner; Nelson Sabates; Kathleen Billman; Barry Kapik; Ken Green; Frances E Kane Journal: Ophthalmology Date: 2012-12-04 Impact factor: 12.079
Authors: Sherif A Gaballa; Uday B Kompella; Omar Elgarhy; Ali M Alqahtani; Barbara Pierscionek; Raid G Alany; Hamdy Abdelkader Journal: Drug Deliv Transl Res Date: 2021-06 Impact factor: 4.617
Authors: Francisco J Goñi; Ingeborg Stalmans; Philippe Denis; Jean-Philippe Nordmann; Simon Taylor; Michael Diestelhorst; Antonio R Figueiredo; David F Garway-Heath Journal: Ophthalmol Ther Date: 2016-05-10
Authors: Yu-Chi Liu; Anthony Herr Cheun Ng; Xu Wen Ng; Peng Yan; Subbu S Venkatraman; Jodhbir S Mehta; Tina T Wong Journal: Transl Vis Sci Technol Date: 2017-10-05 Impact factor: 3.283